Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE vs NORPACE CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.
Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.
Pseudobulbar affect (PBA) - FDA approved
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Off-label: prevention of atrial fibrillation recurrence, maintenance of sinus rhythm in atrial flutter
One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.
Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.
Dextromethorphan: 2-4 hours (extensive metabolizers); quinidine: 6-8 hours (inhibits CYP2D6, prolonging dextromethorphan half-life in poor metabolizers to >20 hours)
Terminal elimination half-life: 6-12 hours (normal renal function); prolonged to 12-20 hours in renal impairment. In coronary artery disease, half-life may be extended due to reduced clearance.
Dextromethorphan is primarily metabolized by CYP2D6 to dextrorphan; quinidine is a potent CYP2D6 inhibitor at low doses.
Primarily hepatic via CYP3A4; also excreted renally.
Renal: quinidine 15-25% unchanged, dextromethorphan <1% unchanged; biliary/fecal: quinidine metabolites ~5%, dextromethorphan metabolites ~60-80% as dextrorphan conjugates
Renal (50-57% unchanged), hepatic metabolism (30-40%), fecal (<10%). Dose adjustment required for Cr Cl <40 m L/min.
Dextromethorphan: ~60-70% (albumin); quinidine: 80-90% (albumin, alpha-1-acid glycoprotein)
30-50% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins.
Dextromethorphan: 5-6 L/kg; quinidine: 2-3 L/kg
0.6-1.2 L/kg; larger Vd in heart failure (up to 2.0 L/kg) due to reduced tissue binding.
Oral: dextromethorphan ~11% (extensive first-pass metabolism; increased to >50% when coadministered with quinidine); quinidine ~70-80%
Oral immediate-release: 70-80%; extended-release: 60-70% (first-pass metabolism). IV: 100%.
For creatinine clearance (Cr Cl) 30–59 m L/min: reduce dose to one capsule once daily. For Cr Cl <30 m L/min: not recommended.
GFR 30-50 m L/min: 200 mg loading dose, then 100 mg every 12 hours. GFR 15-30 m L/min: 200 mg loading dose, then 100 mg every 24 hours. GFR <15 m L/min: 200 mg loading dose, then 100 mg every 48-72 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: not recommended (quinidine is extensively metabolized by the liver).
Child-Pugh Class B or C: Reduce dose by 50% and titrate carefully; monitor ECGs.
Safety and efficacy in pediatric patients have not been established; not recommended for use in children.
Not recommended for pediatric use; safety and efficacy not established.
Initiate at one capsule once daily; titrate cautiously. Monitor for QT prolongation and anticholinergic effects. Lower doses may be required due to age-related renal and hepatic decline.
Initiate at lower dose (e.g., 100 mg every 12 hours of controlled-release) due to increased risk of anticholinergic effects and renal impairment; monitor renal function and QT interval.
None.
May cause widening of QRS complex and prolongation of QT interval, increasing risk of torsade de pointes and sudden death. Avoid use with other drugs that prolong QT interval. Use only for life-threatening arrhythmias.
CNS depression: may cause dizziness, somnolence; avoid alcohol.,Cardiotoxicity: quinidine may cause QT prolongation; monitor ECG.,Serotonin syndrome: risk with concurrent serotonergic drugs.,Hepatic impairment: use with caution.,Renal impairment: not recommended in severe renal disease.
Can worsen arrhythmias (proarrhythmic); monitor ECG, electrolytes; adjust dose in renal/hepatic impairment; avoid in patients with pre-existing QT prolongation, hypokalemia, or bradycardia.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days.,Concomitant use with other drugs that prolong QT interval.,Known hypersensitivity to dextromethorphan or quinidine.,Complete atrioventricular block without pacemaker.,History of drug-induced torsades de pointes.
Pre-existing second- or third-degree AV block (unless pacemaker), cardiogenic shock, congenital QT prolongation, concurrent use of other QT-prolonging drugs, hypersensitivity to disopyramide.
Avoid grapefruit and grapefruit juice as they may increase plasma levels of quinidine, raising risk of toxicity including QT prolongation. Avoid excessive alcohol consumption as it may exacerbate CNS depression.
Avoid grapefruit juice as it may increase disopyramide levels. High-fat meals may delay absorption but do not significantly affect overall bioavailability; take consistently with or without food.
First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethorphan hydrobromide not associated with major malformations; quinidine sulfate may cause fetal bradycardia and hypoglycemia due to quinidine's antiarrhythmic effects. Overall: No adequate human studies; use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Second and third trimesters: May cause fetal bradycardia, hypoglycemia, and preterm labor due to beta-blockade effects; avoid use unless benefit outweighs risk.
Dextromethorphan: Likely excreted in breast milk in low amounts; M/P ratio not reported. Quinidine: Excreted in breast milk; M/P ratio approximately 0.71. Potential for infant quinidine toxicity (cinchonism, arrhythmias). Avoid breastfeeding during maternal quinidine therapy.
Disopyramide is excreted in human breast milk; M/P ratio approximately 0.5-1.0. Limited data suggests low infant exposure but potential for hypoglycemia and bradycardia; caution advised. American Academy of Pediatrics considers disopyramide compatible with breastfeeding with monitoring.
No specific pharmacokinetic studies in pregnancy; increased renal clearance of dextromethorphan in third trimester may lower exposure. For quinidine, plasma protein binding decreases in pregnancy, potentially increasing free drug fraction. Dose adjustment not recommended due to lack of data; titrate based on clinical response and toxicity monitoring.
No formal dosing guidelines established. Pregnancy may alter pharmacokinetics (increased volume of distribution and clearance), potentially requiring dose adjustments. Therapeutic drug monitoring is recommended to maintain trough disopyramide levels between 2-5 mcg/m L. Due to proarrhythmic risks, use lowest effective dose and monitor closely.
Monitor for QT prolongation with baseline and periodic ECG, especially in patients with hypokalemia, hypomagnesemia, or bradycardia. Avoid use with CYP3A4 inhibitors (e.g., ketoconazole) or CYP2D6 inhibitors (e.g., paroxetine) due to quinidine metabolism. Quinidine is a potent CYP2D6 inhibitor; caution with concurrent CYP2D6 substrates like tricyclic antidepressants. Onset of pseudobulbar affect improvement may take weeks; titrate dose gradually.
NORPACE CR (disopyramide phosphate) is a Class Ia antiarrhythmic with strong anticholinergic effects; monitor for urinary retention, constipation, and dry mouth. It has negative inotropic effects and should be avoided in patients with compensated heart failure or cardiomyopathy. Dosage adjustment required in renal impairment (Cr Cl <40 m L/min). Therapeutic drug monitoring recommended (target 2-5 mcg/m L).
Take this medication exactly as prescribed; do not double doses if missed.,Avoid grapefruit juice as it may increase side effects.,Report any signs of irregular heartbeat (palpitations, dizziness, fainting) or allergic reactions (rash, difficulty breathing).,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Do not stop abruptly; dose reduction should be gradual under medical supervision.,Inform all healthcare providers about this medication, especially before any surgery or dental procedure.
Do not crush or chew extended-release tablets; swallow whole.,Take at regular 12-hour intervals to maintain steady drug levels.,Avoid driving or operating machinery until you know how this medication affects you (may cause dizziness or blurred vision).,Report signs of hypoglycemia (sweating, shakiness) in diabetic patients, as disopyramide can lower blood sugar.,Maintain adequate fluid intake to prevent constipation.,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.
"The coadministration of nisoldipine, a calcium channel blocker, with quinidine, a Class Ia antiarrhythmic, results in a significant reduction in quinidine serum concentrations. This interaction is primarily due to nisoldipine-induced enhancement of hepatic quinidine metabolism via cytochrome P450 3A4 induction, leading to subtherapeutic quinidine levels and potential loss of antiarrhythmic efficacy. Clinically, patients may experience breakthrough arrhythmias or inadequate suppression of atrial or ventricular arrhythmias."
"Scopolamine, an anticholinergic agent, and Quinidine, a Vaughan-Williams Class Ia antiarrhythmic with anticholinergic properties, exhibit additive anticholinergic effects when coadministered. This synergy can lead to enhanced peripheral and central anticholinergic adverse effects, including dry mouth, blurred vision, urinary retention, constipation, tachycardia, confusion, and cognitive impairment, particularly in elderly patients. The risk is significant as both drugs block muscarinic acetylcholine receptors, potentially precipitating anticholinergic toxicity."
"Vernakalant, a multi-ion channel blocker primarily used for atrial fibrillation conversion, can inhibit cytochrome P450 (CYP) 3A4, the major enzyme responsible for the metabolism of quinidine. This results in elevated plasma concentrations of quinidine, increasing the risk of quinidine-related cardiotoxicity, including QTc prolongation, torsade de pointes, and other ventricular arrhythmias. The interaction may also potentiate vagolytic effects and negative inotropy, leading to hemodynamic compromise."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE vs NORPACE CR, answered by our medical review team.
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is a Antiarrhythmic (Class Ia) that works by Dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; quinidine is a CYP2D6 inhibitor that increases dextromethorphan bioavailability.. NORPACE CR is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; decreases myocardial excitability and conduction velocity, and prolongs refractory period by blocking sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE and NORPACE CR depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is: One capsule (dextromethorphan 20 mg/quinidine 10 mg) orally once daily, with a maximum dose of two capsules per day.. The standard adult dose of NORPACE CR is: Disopyramide controlled-release: 200 mg orally every 12 hours; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE and NORPACE CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE is classified as Category A/B. First trimester: Limited human data; animal studies show quinidine sulfate associated with increased risk of fetal malformations at high doses. Second/third trimester: Dextromethor. NORPACE CR is classified as Category C. FDA Pregnancy Category C. First trimester: Evidence of teratogenicity in animal studies (increased fetal resorption and skeletal abnormalities) but no adequate human studies. Secon. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.